Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Pechala's Reports
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vivalis SA Announces New EB66 Cell Line Services and License Option Agreement with Glaxosmithkline Plc

Monday, 8 Apr 2013 11:40am EDT 

Vivalis SA announced that it has signed an EB66 cell line research services and license option agreement with Glaxosmithkline Plc to establish the feasibility of producing a new viral vaccine against an important viral disease using EB66 with an option to license EB66 cell line for similar viruses of the same family. Financial terms of the agreement were not disclosed. 

Latest Key Developments in Pharmaceuticals

Company Quote

-0.69 -1.27%
11 Jul 2014